United States · Bill · S
S. 5002 (117th)
FDA Modernization Act 2.0
Introduced
29 September 2022
Last action
—
Status
Held at the desk.
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
FDA Modernization Act 2.0 This bill authorizes the use of certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the Food and Drug Administration to investigate the safety and effectiveness of a drug. The bill also removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
6 official files
Considered and Passed Senate (text)
Considered and Passed Senate · EN · 29 September 2022
Considered and Passed Senate (PDF)
Considered and Passed Senate · EN · 29 September 2022
Engrossed in Senate (text)
Engrossed in Senate · EN · 29 September 2022
Engrossed in Senate (PDF)
Engrossed in Senate · EN · 29 September 2022
Passed Senate
summary · EN · 29 September 2022
Introduced in Senate
summary · EN · 29 September 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/5002
- Open data entity: https://api.congress.gov/v3/bill/117/s/5002